US President Donald Trump says he’s been taking hydroxychloroquine, a controversial anti-malarial drug touted as, for “about a week and a half,” despite a lack of evidence it can prevent coronavirus infection.
The Food and Drug Administration has granted the drug, which is also used to treat conditions like lupus and rheumatoid arthritis, emergency use authorization status, allowing it to be given to patients with has been known to cause heart rhythm problems.in clinical trials or hospital settings. However, the FDA cautions against its use outside of these circumstances because it
During a White House briefing on Monday, Trump discussed the treatment noting “many, many” frontline workers were taking the drug, before stating “I happen to be taking it.” When a reporter asked why, Trump said “because I think it’s good, I’ve heard a lot of good stories.” He clarified he’s taking both zinc and hydroxychloroquine and said he hasn’t been exposed to COVID-19.
When asked if the treatment was recommended by the White House doctor, Trump said “yeah, White House doctor, didn’t recommend — no, I asked him “what do you think?” He said, “well, if you’d like it.” I said, “yeah, I’d like to take it.’
“A lot of people are taking it, a lot of front line workers are taking hydroxychloroquine,” he said. “There’s a very good chance this has an impact, especially early on.”
Taking hydroxychloroquine as a preventative for COVID-19 isn’t covered by the FDA’s emergency use authorization policy.
Trump has long championed the potential of hydroxychloroquine when taken with azithromycin, an antibiotic, tweeting in March that the combination treatment had a “real chance to be one of the biggest game changers in the history of medicine.”
The weight of scientific evidence currently suggests COVID-19 patients don’t see improved clinical outcomes on hydroxychloroquine. Studies have shown increases in mortality and combination studies, with azithromycin, also failed to show benefits. Adverse events are also more common on those receiving the drug. There’s a varied clinical picture for COVID-19 patients, with symptoms ranging from mild to severe, and adequately assessing the effect of hydroxychloroquine requires trialing it in multiple patient populations.
Gaetan Burgio, a geneticist and infectious disease expert at Australian National University, has been following the clinical data being published about hydroxychloroquine and says “there is now a increasing body of evidence demonstrating hydroxychloroquine does not offer efficacy for protection against COVID-19 prophylactically and curatively.”
In regards to Trump, he notes “there is no evidence it will protect him against COVID-19.”
Researchers are still looking to understand how hydroxychloroquine in combination with azithromycin and zinc may benefit patients with COVID-19. There are more than 160 hydroxychloroquine trials ongoing, with the majority assessing the effects of the drug in battling COVID-19 infection, according to the National Institutes of Health’s clinical trial website. Only a handful of these studies are assessing the effects of the drug as a prophylactic. A systematic review, published in the International Journal of Rheumatic Diseases in April, suggested there is a “dearth of evidence” to support its use as a preventative treatment option.
Coronavirus reopenings: How it looks as lockdowns ease around the world
- Pandemic thriller Utopia on Amazon might be the perfect viewing
- 2021 Jaguar F-Pace refreshed with new styling, luxury and tech
- 2020 Halloween full moon: This year’s spooky spectacle brings a rare twist
- The best minimalist wallet for 2020
- NASA chief calls for prioritizing Venus after surprise find hints at alien life
- YouTube is adding a new Shorts feature to rival TikTok and Instagram Reels
- Paul Rudd, world’s youngest 51-year-old, tells fellow kids to mask up
- Jonathan Majors to join MCU as villain Kang the Conquerer, report says
- TikTok ban won’t prevent employees from being paid, US says in filing